



**NYSE American:VNRX
Corporate Deck**

May 2026

Forward Looking Statements and Disclaimer

Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition’s predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to Volition’s development activities and business strategy, including regulatory approvals, commercialization, product launches, publications, market acceptance and reimbursement; statements concerning industry trends, industry size, anticipated demand for Volition’s products and services, market opportunity, projected test volumes and the products of Volition’s competitors; statements relating to manufacturing forecasts and the potential impact of Volition’s relationships with contract manufacturers, original equipment manufacturers, distributors, licensees and other commercial counterparties on its business; assumptions regarding the future cost and potential benefits of Volition’s research and development efforts; forecasts of Volition’s liquidity position, available cash resources and financing plans; statements regarding current or future licensing, distribution, supply, co-marketing or other commercial arrangements or discussions, including potential milestone payments, royalties, recurring revenues and other commercial economics; statements regarding government-backed, investigator-led or third-party programs involving Volition’s products or technology; and statements relating to the assumptions underlying any of the foregoing. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Nu.Q® and Capture-PCR™, Capture-Seq™, rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this document are the property of their respective owners. Additionally, unless otherwise specified, all references to “\$” refer to the legal currency of the United States of America.

Recent Achievements



- Cat Paper Submitted; if published a \$5 million contractual milestone payment expected
- Fujifilm Vet Systems launch on automated i10 platform



- Expansion into non-sepsis disease areas
 - Mayo Clinic Publication in Trauma
 - KOL Preprint for Hidradenitis Suppurativa (HS)
- DETECSEPs on track for first patient Q3



- Reimbursement Submission in Preparation
- Certification Completed at three French hospitals
- Manuscripts submitted for peer review and publication

- Manuscript in Review



- Research ongoing into competing conditions / other clinical utility such as MRD
- KOLs being cultivated
- Technical Evaluations completed / ongoing / in preparation



- Co-Marketing Agreement in place with Hologic
- Some larger scale programs in confidential discussions

Executive Summary

Our mission is to save lives and improve outcomes for millions of people and animals worldwide.

VolitionRx

NYSE American: VNRX

Medical Devices

IP Powerhouse

Focus

Licensing IP

Cancer, Sepsis

Low-cost testing

Commercial

Worldwide Animal

\$23M in licensing

\$1M of Rev Q1 2026

Large Unmet Needs

Cancer

Sepsis

Veterinarian

Team

100s yrs experience

49 patent families*

15 years together

Catalysts

Cancer Licensing


NETs Licensing

\$5m Cat Milestone


Derisked R&D and Commercial Strategy

* As of 31st March 2026

Measuring chromatin fragments



Cancer



NETs

Global Experts in Quantifying Nucleosomes

Low-cost routine tests

Platform agnostic; can be adapted to any diagnostic workflow



6 hours

Manual



45 minutes

Automated



<10 minutes

Point of Care



<15 minutes

Lateral Flow

Asset light - no need for own machines, labs or sales reps

Commercialization Strategy

Underlying principles: low capex, low opex business model focused on commercial partnerships and out-licensing

R&D

- ❶ R&D conducted by Volition and its research partners
- ❷ Monetize IP through licensing agreements with:
 - ❶ upfront payments,
 - ❷ milestone payments,
 - ❸ recurring revenue from sales of key components & royalties

Licensing and partnering capabilities:

- ❶ *Broad geographic reach*
- ❷ *Large installed base*
- ❸ *Experience of tech transfer*
- ❹ *Regulatory and clinical affairs*
- ❺ *Large sales and marketing teams*



2026: Targeting multiple licensing deals in the human space

Recent Deals Signed

werfen

HOLOGIC®
Diagenode



- **Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") for Nu.Q® NETs**
- **Co-Marketing and Services Agreement for Nu.Q® Discover**
- **First Sale of the Nu.Q® Cancer Assays for Clinical Certification; Reimbursement Submission in Preparation for Routine Clinical Use**

69 patents granted with coverage up to 2044¹

	<u>TAM²</u>	<u>Regulation</u>	<u>Product</u>	<u>Status</u>	<u>Strategy</u>
nu·q cancer	\$4Bn	Lab Developed	Screening/ Management	Reimbursement Submission	Sales & Licensing
capture seq	\$23Bn	CE Mark/ FDA	Multi-Cancer Early Detection	Proof of Concept	Sales & Licensing
nu·q nets	>\$3Bn ICU/ED	CE Mark/ FDA	NETosis	First sales in EU	Sales & Licensing
nu·q vet	\$170Mn	Non-Regulated	Companion Animal Tests	Launched Worldwide	Licensing
nu·q discover	~\$1Bn	Research Use	Service & Assay Kit	Launched Worldwide	Sales

* 1. As of 31st March 2026. 2. Data on File: Volition TAM Model

A world first in **isolating 99% pure tumor-derived DNA** from a liquid biopsy¹ **Volition**

capture seq

- World first isolation of transcription factor-DNA from blood
- World first preparation of pure tumor-derived DNA sequence data sets
- A novel class of thousands of new biomarkers
- Compelling proof-of-concept clinical data

Early detection

Find cancer early

Improve outcomes

Finding MRD after treatment

Adjust treatment

Improve outcomes

Treatment monitoring

Assess treatment response












Adjust treatment









Improve outcomes

1. Pamart et al., <https://doi.org/10.21203/rs.3.rs-8047483/v2>

Projected Catalysts

Multiple licensing deals in 2025 and 2026

	Catalyst	2025	2026	2027
	Licensing cancer technology			
	Reimbursement / Adoption into routine clinical practice			
	Adoption into national program(s)			
	Licensing Multi-Cancer Early Detection			
	<hr/>			
	Licensing for Human NETosis / Sepsis			
	Sales of CE marked product in Europe			
	Potential \$5M milestone payment linked to use in felines			
	Automation of Test			
	Wellness plan adoption to drive sales ramp			
	Co-Marketing agreement			
	Distribution agreement			
	Assays used in Phase III clinical studies with pharma			

-  Multiple products already launched
-  Proven Licensing model, validated in Vet
-  Strong IP
-  Multiple multi-billion TAM markets
-  Low-cost, scalable platform with high margins
-  Asset light - no need for own machines, labs, or sales reps
-  In confidential licensing discussions with **more than a dozen** large diagnostic and liquid biopsy companies worldwide, first deals signed in Q3 2025
-  Anticipate use in ***routine*** clinical practice in 2026

Thank You!